Arctic Bioscience AS (DE:9TD) has released an update.
Arctic Bioscience, a biotech firm focusing on bioactive marine compounds, is set to present results from the HeROPA clinical trial in a webcast on October 16, 2024, led by CEO Christer L. Valderhaug and Medical Director Runhild Gammelsæter. The company is actively developing a new drug, HRO350, aimed at treating mild-to-moderate psoriasis and markets nutraceuticals globally under the ROMEGA® brand.
For further insights into DE:9TD stock, check out TipRanks’ Stock Analysis page.